Diaceutics

1. 24 Sep 26
   Diaceutics and Syndax expand Relay partnership

   Expanded partnership to support the commercialization of a diagnostic-driven therapy and help identify and treat eligible patients sooner

   RNS 9788006 ↗
2. 22 Sep 26
   Half-year Results

   Interim Results for the six months ended 30 June 2026

   RNS 9783201 ↗
3. 02 Sep 26
   PDMR Shareholding/SIP & Total Voting Rights Director buys

   PDMR Shareholding/Share Incentive Plan and Total Voting Rights

   RNS 9752514 ↗
4. 20 Aug 26
   Diaceutics and PCC launch NGS Concordance Study

   Diaceutics and PCC launch NGS Concordance Study to advance precision oncology and support informed biomarker testing

   RNS 9731584 ↗
5. 29 Jul 26
   75% ARR Growth Drives Revenue & Profit Visibility

   Strong ARR growth of 75% drives H2 2026 revenue and profit visibility

   RNS 9692255 ↗
6. 26 May 26
   Final Results

   Revenue growth of 24% on a constant currency basis to £38.4 million in FY 2025

   RNS 9583877 ↗
7. 16 Apr 26
   Related Party Transaction - Lease Extension

   New York, Belfast and London, 16 April 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces that it has agreed an extension to its existing property lease agreement for its Belfast...

   RNS 9524223 ↗
8. 03 Feb 26
   PDMR Shareholding/Share Incentive Plan & TVR Director buys

   PDMR Shareholding/Share Incentive Plan and Total Voting Rights

   RNS 9404236 ↗
9. 15 Jan 26
   Full Year 2025 Trading Update

   Reported revenues expected to be £38.5 million, representing 20% growth and a return to profitability

   RNS 9354456 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.